NCT01929980View on ClinicalTrials.gov

Bortezomib to Treat Significant Complication of HSCT

PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Allogeneic Stem Cell TransplantationRefractory Autoimmune Cytopenia(s)
Interventions
DRUG

Bortezomib

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT01929980 - Bortezomib to Treat Significant Complication of HSCT | Biotech Hunter | Biotech Hunter